open access

Vol 15, No 5 (2010)
Published online: 2010-09-01
Submitted: 2010-05-20
Get Citation

Multimodality treatment of locally advanced soft-tissue sarcomas of the extremities

Vincenzo Ravo, Immacolata Marrone, Anna Morra, Roberto Manzo, Paola Murino, Fabrizio Cammarota, Paolo Muto
DOI: 10.1016/j.rpor.2010.08.006
·
Rep Pract Oncol Radiother 2010;15(5):119-124.

open access

Vol 15, No 5 (2010)
Published online: 2010-09-01
Submitted: 2010-05-20

Abstract

Background

Adjuvant radiotherapy (RTE) still has a fundamental role as a post-operative treatment of locally advanced soft tissues sarcomas of the extremities. Moreover the employment of combined modalities in locally advanced soft tissues sarcomas of the extremities allow to maximize the chance of local cure even in difficult presentation cases, and possibly improve survival, especially in high-risk disease patients. In patients with sarcomas of the extremities in which definitive surgery has not been radical (with positive or “close” margins) radiotherapy can improve the results in terms of Disease Free Survival (DFS) and, together with chemotherapy, of Overall Survival (OS). We recommend radiotherapy in case of deep tumor location, inadequate surgical margins and grade 3 tumour; for positive or “marginal (or close)” excision (that means inadequate surgery) or in selected patients with a bad prognosis, we believe that a multidisciplinary approach can be preferable.

Introduction

Adjuvant radiotherapy (RTE) still has a fundamental role as a post-operative treatment. In patients with sarcomas of the extremities in whom definitive surgery has been or not radical (positive or “close” margins), radiotherapy with chemotherapy can improve the results in terms of Disease Free Survival (DFS) and Overall Survival (OS), while RTE alone seems to improve local control.

Materials and methods

From 1/2000 to 12/2005 we treated 34 patients affected by locally advanced sarcomas of the upper or lower extremities with radiotherapy (doses ranging from 54 to 66[[ce:hsp sp="0.25"/]]Gy) and chemotherapy in 18/34 with an adjuvant scheme that consisted in Epirubicine (120[[ce:hsp sp="0.25"/]]mg/m2) plus Ifosfamide (7000–9000[[ce:hsp sp="0.25"/]]mg/m2).

Results

Disease Free Survival (DFS) and the Overall Survival (OS) rates were 76% and 82%, respectively. Eighteen patients developed one or more long-term side effects. Most of these complications were mild: all patients experienced only erithema, edema, local sclerosis or moderate pain.

Conclusion

Radiotherapy has an important role as a post-operative treatment also when surgery was non-radical. It improves local control more in patients with high-grade sarcomas of the extremity with positive or close margins. It is still difficult to assess the role of adjuvant chemotherapy.

Abstract

Background

Adjuvant radiotherapy (RTE) still has a fundamental role as a post-operative treatment of locally advanced soft tissues sarcomas of the extremities. Moreover the employment of combined modalities in locally advanced soft tissues sarcomas of the extremities allow to maximize the chance of local cure even in difficult presentation cases, and possibly improve survival, especially in high-risk disease patients. In patients with sarcomas of the extremities in which definitive surgery has not been radical (with positive or “close” margins) radiotherapy can improve the results in terms of Disease Free Survival (DFS) and, together with chemotherapy, of Overall Survival (OS). We recommend radiotherapy in case of deep tumor location, inadequate surgical margins and grade 3 tumour; for positive or “marginal (or close)” excision (that means inadequate surgery) or in selected patients with a bad prognosis, we believe that a multidisciplinary approach can be preferable.

Introduction

Adjuvant radiotherapy (RTE) still has a fundamental role as a post-operative treatment. In patients with sarcomas of the extremities in whom definitive surgery has been or not radical (positive or “close” margins), radiotherapy with chemotherapy can improve the results in terms of Disease Free Survival (DFS) and Overall Survival (OS), while RTE alone seems to improve local control.

Materials and methods

From 1/2000 to 12/2005 we treated 34 patients affected by locally advanced sarcomas of the upper or lower extremities with radiotherapy (doses ranging from 54 to 66[[ce:hsp sp="0.25"/]]Gy) and chemotherapy in 18/34 with an adjuvant scheme that consisted in Epirubicine (120[[ce:hsp sp="0.25"/]]mg/m2) plus Ifosfamide (7000–9000[[ce:hsp sp="0.25"/]]mg/m2).

Results

Disease Free Survival (DFS) and the Overall Survival (OS) rates were 76% and 82%, respectively. Eighteen patients developed one or more long-term side effects. Most of these complications were mild: all patients experienced only erithema, edema, local sclerosis or moderate pain.

Conclusion

Radiotherapy has an important role as a post-operative treatment also when surgery was non-radical. It improves local control more in patients with high-grade sarcomas of the extremity with positive or close margins. It is still difficult to assess the role of adjuvant chemotherapy.

Get Citation

Keywords

Radiotherapy; Chemotherapy; Sarcomas of extremities

About this article
Title

Multimodality treatment of locally advanced soft-tissue sarcomas of the extremities

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 15, No 5 (2010)

Pages

119-124

Published online

2010-09-01

DOI

10.1016/j.rpor.2010.08.006

Bibliographic record

Rep Pract Oncol Radiother 2010;15(5):119-124.

Keywords

Radiotherapy
Chemotherapy
Sarcomas of extremities

Authors

Vincenzo Ravo
Immacolata Marrone
Anna Morra
Roberto Manzo
Paola Murino
Fabrizio Cammarota
Paolo Muto

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl